Mountain Valley MD (CSE: MVMD- OTCQB: MVMDF) CEO Dennis Hancock and Director of Life Sciences Mike Farber joined Steve Darling from Proactive with news the company is planning to start husbandry animal trials with a third-party research organization to validate injectable solubilized Ivermectin technology to treat a broad category of animal parasites.
Hancock telling Proactive how significant this move is for the company and that they have brought on a new veterinarian advisor. Farber shares his thoughts on this trial and why he feels this will prove valuable to control outbreaks of influenza viruses.